CGTXCognition Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $1.02 · now $1.02 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CGTX has typically landed between $0.61 and $1.56 — a range of −40.1% to +52.7% from the issuance price $1.02.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,217 overlapping 1 month windows · 2021-10-082026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($1.02) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CGTX has typically landed a month from the 2026-09-16 close of $1.02 — the range is history, not a prediction.

$0.6108worst · -40.1%$1.56best · +52.7%
  • now $1.02 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $0.9485 (-7.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $0.8299$1.07
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $0.6108$1.56
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,217 windows spanning 2021-10-08 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-07-09−71.7%−71.7%+15.0%
2024-07-12−71.3%−72.4%+19.7%
2024-07-26−70.3%−76.9%+0.0%
3 best
2025-07-29+356.6%−12.6%+374.5%
2025-07-31+314.8%+0.0%+442.8%
2025-07-28+299.9%−18.1%+344.7%

1,217 overlapping windows · 2021-10-082026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
40%
−6.0%
n=5
Feb
0%
−19.0%
n=5
Mar
20%
−7.3%
n=5
Apr
80%
+12.6%
n=5
May
40%
−7.7%
n=5
Jun
20%
−3.6%
n=5
Jul
20%
+1.4%
n=5
Aug
60%
+60.7%
n=5
Sep
0%
−18.8%
n=5
Oct
50%
+1.2%
n=4
Nov
20%
+10.1%
n=5
Dec
40%
+10.3%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-04-16: 3 insider purchases, $32K — Doyle John Brendan, Caggiano Anthony, Ricciardi Lisa2026-04: 3 open-market purchases, $32K↑ buys↓ salesofficer Doyle John Brendan — Purchase on 2026-04-16, filed 4 days after the tradeofficer Caggiano Anthony — Purchase on 2026-04-16, filed 4 days after the tradedirector Ricciardi Lisa — Purchase on 2026-04-16, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-04-16Doyle John BrendanofficerPurchase10,000 @ $1.13$11K+1.6% of holding−2.6%not yet — horizon still open627,509Form 4 · filed 4 days after the trade
2026-04-16Caggiano AnthonyofficerPurchase10,000 @ $1.11$11K+1.2% of holding−2.6%not yet — horizon still open874,906Form 4 · filed 4 days after the trade
2026-04-16Ricciardi LisadirectorPurchase9,175 @ $1.10$10K+0.5% of holding−2.6%not yet — horizon still open1,715,851Form 4 · filed 4 days after the trade
2025-01-31Ricciardi LisadirectorPurchase38,851 @ $0.77$30Kownership Δ n/a−37.7%−6.8%38,851Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

46 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-17Fletcher Aaron G.L.directorAward / grant25,00081,229Form 4
2026-06-17RICHSTONE ELLEN BdirectorAward / grant25,00083,500Form 4
2026-06-17Wallace PeggydirectorAward / grant25,000111,461Form 4
2026-06-17Monia Brett PdirectorAward / grant25,00073,500Form 4
2026-06-17Khattar Jack A.directorAward / grant25,00073,500Form 4
2026-05-01Doyle John BrendanofficerWithheld for tax8,567618,942Form 4
2026-02-15Ricciardi LisadirectorWithheld for tax5,8501,706,676Form 4
2026-02-15Caggiano AnthonyofficerWithheld for tax4,680864,906Form 4
2026-02-15Doyle John BrendanofficerWithheld for tax1,560617,509Form 4
2026-02-04Ricciardi LisadirectorWithheld for tax51,7041,712,526Form 4
2026-02-04Doyle John BrendanofficerWithheld for tax26,921619,069Form 4
2026-02-04Caggiano AnthonyofficerWithheld for tax26,919869,586Form 4
2026-02-03Ricciardi LisadirectorWithheld for tax26,0361,764,230Form 4
2026-02-03Caggiano AnthonyofficerWithheld for tax11,488896,505Form 4
2026-02-03Doyle John BrendanofficerAward / grant200,000645,990Form 4
2026-02-03Caggiano AnthonyofficerAward / grant400,000907,993Form 4
2026-02-03Ricciardi LisadirectorAward / grant800,0001,790,266Form 4
2025-12-18Ricciardi LisadirectorWithheld for tax23,400990,266Form 4
2025-12-18Caggiano AnthonyofficerWithheld for tax20,280507,993Form 4
2025-12-18Doyle John BrendanofficerWithheld for tax9,360445,990Form 4
2025-12-18Caggiano AnthonyofficerAward / grant65,000528,273Form 4
2025-12-18Doyle John BrendanofficerAward / grant30,000455,350Form 4
2025-12-18Ricciardi LisadirectorAward / grant75,0001,013,666Form 4
2025-09-19Fletcher Aaron G.L.directorOption exercise7,72956,229Form 4
2025-09-19Fletcher Aaron G.L.directorOption exercise7,7290Form 4
2025-07-29Ricciardi LisadirectorWithheld for tax23,400938,666Form 4
2025-07-29Caggiano AnthonyofficerWithheld for tax20,281463,273Form 4
2025-07-29Doyle John BrendanofficerWithheld for tax9,360425,350Form 4
2025-07-29Doyle John BrendanofficerAward / grant30,000434,710Form 4
2025-07-29Caggiano AnthonyofficerAward / grant65,000483,554Form 4
2025-07-29Ricciardi LisadirectorAward / grant75,000962,066Form 4
2025-06-18Fletcher Aaron G.L.directorAward / grant34,00048,500Form 4
2025-06-18Khattar Jack A.directorAward / grant34,00048,500Form 4
2025-06-18Wallace PeggydirectorAward / grant34,00086,461Form 4
2025-06-18Kreis Leslie W.directorAward / grant34,00048,500Form 4
2025-06-18Monia Brett PdirectorAward / grant34,00048,500Form 4
2025-06-18RICHSTONE ELLEN BdirectorAward / grant34,00058,500Form 4
2025-05-01Doyle John BrendanofficerWithheld for tax9,692404,710Form 4
2025-02-15Ricciardi LisadirectorWithheld for tax6,619887,066Form 4
2025-02-15Caggiano AnthonyofficerWithheld for tax5,296418,554Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.